Table 3: Adverse Events (AEs) in Patients with Clinically Significant Anemia/Blood Lossa Versus those Without (Threshold ≥0.5%)

AEs, n (%)b Patients with Blood Loss (n=932) Patients without Blood Loss (n=50,116)
Any AE 612 (66) 29,222 (58)
GI-Related AEs
Gastric ulcer 14 (1.5) 101 (0.2)
GI hemorrhage 7 (0.8) 33 (< 0.1)
Esophageal ulcer 5 (0.5) 24 (< 0.1)
Melena 12 (1.3) 57 (0.1)
Potential GI-Related AEs
Anemia 82 (8.8) 317 (0.6)
Increase in blood creatinine 16 (1.7) 207 (0.4)
Decrease in hemoglobin 83 (8.9) 120 (0.2)
Decrease in hematocrit 97 (10.4) 228 (0.5)
Decrease in red blood cell count 7 (0.8) 23 (< 0.1)
Hematochezia 9 (1.0) 126 (0.3)
Non-GI-Related AEs
Coronary artery disease 11 (1.2) 144 (0.3)
Myocardial infarction 6 (0.6) 99 (0.2)
Pneumonia 16 (1.7) 202 (0.4)

a Markedly higher, i.e. threefold difference between treatment groups in the incidence of AEs.
b Preferred terms based on MedDRA 11.0.